Molecular docking and identification of G-protein-coupled receptor 120 (GPR120) agonists as SARS COVID-19 MPro inhibitors
Abstract COVID-19 has become a pandemic, and any new drug for treating the disease could save millions of lives. Several drugs already in use for other diseases and medical conditions are repurposed for treating COVID-19 in an attempt to find treatment for the disease without spending research time...
Main Authors: | Sellappan Mohan, Jayagopal Dharani, Ramanathan Natarajan, Arumugam Nagarajan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-07-01
|
Series: | Journal of Genetic Engineering and Biotechnology |
Online Access: | https://doi.org/10.1186/s43141-022-00375-8 |
Similar Items
-
Discovery of Novel and Selective G-Protein Coupled Receptor 120 (GPR120) Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Xuekun Wang, et al.
Published: (2022-12-01) -
Identification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron
by: Xiaodi Zhao, et al.
Published: (2023-11-01) -
Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes
by: Guoxia Ji, et al.
Published: (2021-11-01) -
The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat
by: Maaike Schilperoort, et al.
Published: (2018-03-01) -
GPR120 promotes neutrophil control of intestinal bacterial infection
by: Zheng Zhou, et al.
Published: (2023-12-01)